434 related articles for article (PubMed ID: 26219339)
1. A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.
Beauchamp RL; James MF; DeSouza PA; Wagh V; Zhao WN; Jordan JT; Stemmer-Rachamimov A; Plotkin SR; Gusella JF; Haggarty SJ; Ramesh V
Oncotarget; 2015 Jul; 6(19):16981-97. PubMed ID: 26219339
[TBL] [Abstract][Full Text] [Related]
2. mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.
Beauchamp RL; Erdin S; Witt L; Jordan JT; Plotkin SR; Gusella JF; Ramesh V
J Biol Chem; 2021; 296():100157. PubMed ID: 33273014
[TBL] [Abstract][Full Text] [Related]
3. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma.
Angus SP; Oblinger JL; Stuhlmiller TJ; DeSouza PA; Beauchamp RL; Witt L; Chen X; Jordan JT; Gilbert TSK; Stemmer-Rachamimov A; Gusella JF; Plotkin SR; Haggarty SJ; Chang LS; Johnson GL; Ramesh V;
Neuro Oncol; 2018 Aug; 20(9):1185-1196. PubMed ID: 29982664
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with mTOR kinase inhibitor and dasatinib as a novel therapeutic strategy for vestibular schwannoma.
Sagers JE; Beauchamp RL; Zhang Y; Vasilijic S; Wu L; DeSouza P; Seist R; Zhou W; Xu L; Ramesh V; Stankovic KM
Sci Rep; 2020 Mar; 10(1):4211. PubMed ID: 32144278
[TBL] [Abstract][Full Text] [Related]
5. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.
James MF; Han S; Polizzano C; Plotkin SR; Manning BD; Stemmer-Rachamimov AO; Gusella JF; Ramesh V
Mol Cell Biol; 2009 Aug; 29(15):4250-61. PubMed ID: 19451225
[TBL] [Abstract][Full Text] [Related]
6. Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types.
James MF; Stivison E; Beauchamp R; Han S; Li H; Wallace MR; Gusella JF; Stemmer-Rachamimov AO; Ramesh V
Mol Cancer Res; 2012 May; 10(5):649-59. PubMed ID: 22426462
[TBL] [Abstract][Full Text] [Related]
7. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1).
García-Martínez JM; Alessi DR
Biochem J; 2008 Dec; 416(3):375-85. PubMed ID: 18925875
[TBL] [Abstract][Full Text] [Related]
8. AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.
Guichard SM; Curwen J; Bihani T; D'Cruz CM; Yates JW; Grondine M; Howard Z; Davies BR; Bigley G; Klinowska T; Pike KG; Pass M; Chresta CM; Polanska UM; McEwen R; Delpuech O; Green S; Cosulich SC
Mol Cancer Ther; 2015 Nov; 14(11):2508-18. PubMed ID: 26358751
[TBL] [Abstract][Full Text] [Related]
9. Group I Paks as therapeutic targets in NF2-deficient meningioma.
Chow HY; Dong B; Duron SG; Campbell DA; Ong CC; Hoeflich KP; Chang LS; Welling DB; Yang ZJ; Chernoff J
Oncotarget; 2015 Feb; 6(4):1981-94. PubMed ID: 25596744
[TBL] [Abstract][Full Text] [Related]
10. Molecular alterations in the neurofibromatosis type 2 gene and its protein rarely occurring in meningothelial meningiomas.
Evans JJ; Jeun SS; Lee JH; Harwalkar JA; Shoshan Y; Cowell JK; Golubic M
J Neurosurg; 2001 Jan; 94(1):111-7. PubMed ID: 11147878
[TBL] [Abstract][Full Text] [Related]
11. Osteoglycin promotes meningioma development through downregulation of NF2 and activation of mTOR signaling.
Mei Y; Du Z; Hu C; Greenwald NF; Abedalthagafi M; Agar NYR; Dunn GP; Bi WL; Santagata S; Dunn IF
Cell Commun Signal; 2017 Sep; 15(1):34. PubMed ID: 28923059
[TBL] [Abstract][Full Text] [Related]
12. Serum and glucocorticoid-regulated kinase 1 (SGK1) activation in breast cancer: requirement for mTORC1 activity associates with ER-alpha expression.
Hall BA; Kim TY; Skor MN; Conzen SD
Breast Cancer Res Treat; 2012 Sep; 135(2):469-79. PubMed ID: 22842983
[TBL] [Abstract][Full Text] [Related]
13. Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas.
Lekanne Deprez RH; Bianchi AB; Groen NA; Seizinger BR; Hagemeijer A; van Drunen E; Bootsma D; Koper JW; Avezaat CJ; Kley N
Am J Hum Genet; 1994 Jun; 54(6):1022-9. PubMed ID: 7911002
[TBL] [Abstract][Full Text] [Related]
14. The mTOR pathway controls cell proliferation by regulating the FoxO3a transcription factor via SGK1 kinase.
Mori S; Nada S; Kimura H; Tajima S; Takahashi Y; Kitamura A; Oneyama C; Okada M
PLoS One; 2014; 9(2):e88891. PubMed ID: 24558442
[TBL] [Abstract][Full Text] [Related]
15. The role and regulatory mechanism of IL-1β on the methylation of the NF2 gene in benign meningiomas and leptomeninges.
Wang B; Cui Z; Zhong Z; Sun Y; Yang GY; Sun Q; Bian L
Mol Carcinog; 2016 Dec; 55(12):2268-2277. PubMed ID: 26840621
[TBL] [Abstract][Full Text] [Related]
16. Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis.
Bachir S; Shah S; Shapiro S; Koehler A; Mahammedi A; Samy RN; Zuccarello M; Schorry E; Sengupta S
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33445724
[TBL] [Abstract][Full Text] [Related]
17. Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas.
Dickinson PJ; Surace EI; Cambell M; Higgins RJ; Leutenegger CM; Bollen AW; LeCouteur RA; Gutmann DH
Vet Pathol; 2009 Sep; 46(5):884-92. PubMed ID: 19429976
[TBL] [Abstract][Full Text] [Related]
18. Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas.
Mawrin C; Sasse T; Kirches E; Kropf S; Schneider T; Grimm C; Pambor C; Vorwerk CK; Firsching R; Lendeckel U; Dietzmann K
Clin Cancer Res; 2005 Jun; 11(11):4074-82. PubMed ID: 15930342
[TBL] [Abstract][Full Text] [Related]
19. First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.
Dewan R; Pemov A; Dutra AS; Pak ED; Edwards NA; Ray-Chaudhury A; Hansen NF; Chandrasekharappa SC; Mullikin JC; Asthagiri AR; ; Heiss JD; Stewart DR; Germanwala AV
BMC Cancer; 2017 Feb; 17(1):127. PubMed ID: 28193203
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth.
Burns SS; Akhmametyeva EM; Oblinger JL; Bush ML; Huang J; Senner V; Chen CS; Jacob A; Welling DB; Chang LS
Cancer Res; 2013 Jan; 73(2):792-803. PubMed ID: 23151902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]